What are the possible side effects of icorelatumumab?

Epcoritumab (Epcoritamab) is an immunotherapy drug that may cause some side effects related to the immune system. Although most side effects are mild to moderate, more serious reactions are possible and require close monitoring, especially during treatment.

The most common side effects include cytokine release syndrome (CRS). CRS is an exaggerated immune response that usually occurs early in treatment. Symptoms include fever, hypotension, shortness of breath, fatigue and other symptoms. Fortunately, CRS can be effectively controlled through symptomatic treatment in most cases, but if not treated in time, it may lead to more serious consequences. The occurrence of CRS is often associated with immunotherapy and needs to be managed under physician supervision.

In addition, neurotoxicity is another potential side effect of icarelatumumab. Neurotoxicity may manifest as headache, disturbance of consciousness, tremor and other symptoms, and in severe cases may affect the patient's nervous system function. When patients experience these symptoms, they should inform their doctor immediately and adjust the treatment plan in a timely manner.

Other common side effects include anemia, leukopenia, infection, rash, etc. Most of these side effects are related to enhanced immune system activity. During the course of immunotherapy, the patient's immune system becomes more active, which may cause some damage to the body's normal cells, leading to related adverse reactions.

The side effects of Epcoritumab (Epcoritamab) are mainly related to immune system activation, including cytokine release syndrome, neurotoxicity, anemia, leukopenia, etc. Although most side effects are mild, patients still need to be closely monitored during treatment and any adverse reactions promptly addressed.

Reference materials:https://www.drugs.com/epcoritamab.html